Gene therapy for DMD and pathophysiology of skeletal muscle

Gene therapy for DMD and pathophysiology of skeletal muscle

The dystrophinopathies are pathologies caused by anomalies in the DMD gene encoding for a protein called dystrophin. This protein is absent in Duchenne muscular dystrophy (DMD) while it is present but qualitatively and/or quantitatively altered in the Becker muscular dystrophy (BMD). It is known that the modular structure of dystrophin tolerates large internal deletions. This observation led to the development of two main therapeutic strategies: classical gene therapy with transfer of functional mini- or micro-dystrophin cDNAs in muscles, and targeted exon skipping. Exon skipping strategy, using antisense molecules or gene therapy with AAV-U7, converts an out-of-frame mutation into an in-frame mutation leading to an internally deleted dystrophin. However, in preclinical DMD models, dystrophin restoration by AAV-U7-mediated exon-skipping therapy was shown to drastically decrease after one year in treated animals. We recently showed that pre-treating dystrophic mice muscle with a single dose of peptide-phosphorodiamidate morpholino (PPMO) antisense oligonucleotides led to transitory dystrophin expression at the sarcolemma and allowed efficient maintenance of AAV genomes enhancing significantly the long-term effect of AAV-U7 therapy. Currently, we evaluate this combined treatment by addressing the benefit of systemic injection of therapeutic PPMO and AAV-U7 vector to a severe DMD model (dystrophin/utrophin double-knockout mouse (dKO)). These mice suffer from a much more severe and progressive muscle wasting, heart and diaphragm functions, impaired mobility and premature death, mimicking pathophysiology of DMD patients.

Phenotypic and genomic characterization of Becker dystrophy patients with 45 to 55 exons deletion
BMD displays 1/30000 live births incidence and is characterized by a progressive muscular dystrophy with or without cardiomyopathy. We present a population of 49 BMD patients with a DMD gene in-phase deletion of exons 45 to 55 (BMDdel45-55). As described, 63% of Duchenne patients are eligible to a multiexon skipping therapy by skipping exons 45 to 55 transforming DMD to BMDdel45-55 patients, it is thus crucial to study the genomic/phenotype link in this BMD cohort. Interestingly, emerging regulatory actors as lncRNA are localized in introns 44 and 55. Thus, the specific neo-introns of each patient could create or modify the lncRNA and/or RNA non-coding sequences. The objective of this study is to identify modifier factors involved in phenotypic variability in BMDdel45-55 patients We performed (i) a phenotypic characterization of 49 patients, (ii) a lncRNA profile in 40/49patients and (iii) a WGS in 19/49patients.

Proteins connecting voltage sensing with muscle mass homeostasis
Deciphering the mechanisms governing skeletal muscle plasticity is essential for understanding pathophysiological processes, including muscle dystrophy and age-related sarcopenia. Muscle activity reverses atrophy, but the connection between these processes is unknown. The voltage sensor CaV1.1 has a central role in excitation–contraction coupling, raising the possibility that it may also initiate the adaptive response to changes in muscle activity. We revealed the existence of a transcription switch for the beta subunit of CaV1.1 (CaVβ1) that depends on the innervation state of the muscle. We showed that denervation increases the expression of a novel embryonic isoform, CaVβ1E. CaVβ1E boosts downstream GDF5 signaling to counteract muscle loss after denervation. We reported that aged muscle expresses significantly reduced levels of CaVβ1E and that CaVβ1E overexpression in aging muscle reduces mass waste by rescuing GDF5 expression. Crucially, we also identified human CaVβ1E and showed a tight negative correlation between hCaVβ1E expression and age-related muscle decline in people, suggesting that the mechanisms underlying muscle mass homeostasis are conserved across species. Actually, we have preliminary data indicating a promising therapeutic approach to improve age-related muscle waste due to the implementation of the recombinant protein (rGdf5).


Main publications

  1. Grassi, F, Falcone, S. Report and Abstracts of the 18th Meeting of the Interuniversity Institute of Myology: Virtual meeting, October 21-24, 2021. Eur J Transl Myol. 2021;31 (4):. doi: 10.4081/ejtm.2021.10270. PubMed PMID:34850623 PubMed Central PMC8758965.
  2. Jaque-Fernández, F, Jorquera, G, Troc-Gajardo, J, Pietri-Rouxel, F, Gentil, C, Buvinic, S et al.. Pannexin-1 and CaV1.1 show reciprocal interaction during excitation-contraction and excitation-transcription coupling in skeletal muscle. J Gen Physiol. 2021;153 (12):. doi: 10.1085/jgp.202012635. PubMed PMID:34636893 PubMed Central PMC8515650.
  3. Gargaun, E, Falcone, S, Solé, G, Durigneux, J, Urtizberea, A, Cuisset, JM et al.. The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD. Biomedicines. 2021;9 (2):. doi: 10.3390/biomedicines9020219. PubMed PMID:33672764 PubMed Central PMC7924625.
  4. Forand, A, Muchir, A, Mougenot, N, Sevoz-Couche, C, Peccate, C, Lemaitre, M et al.. Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice. Mol Ther Methods Clin Dev. 2020;17 :695-708. doi: 10.1016/j.omtm.2020.03.011. PubMed PMID:32346547 PubMed Central PMC7177166.
  5. Traoré, M, Gentil, C, Benedetto, C, Hogrel, JY, De la Grange, P, Cadot, B et al.. An embryonic CaVβ1 isoform promotes muscle mass maintenance via GDF5 signaling in adult mouse. Sci Transl Med. 2019;11 (517):. doi: 10.1126/scitranslmed.aaw1131. PubMed PMID:31694926 .
  6. Fongy, A, Falcone, S, Lainé, J, Prudhon, B, Martins-Bach, A, Bitoun, M et al.. Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model. Sci Rep. 2019;9 (1):1580. doi: 10.1038/s41598-018-38184-0. PubMed PMID:30733559 PubMed Central PMC6367339.
  7. Franck, A, Lainé, J, Moulay, G, Lemerle, E, Trichet, M, Gentil, C et al.. Clathrin plaques and associated actin anchor intermediate filaments in skeletal muscle. Mol Biol Cell. 2019;30 (5):579-590. doi: 10.1091/mbc.E18-11-0718. PubMed PMID:30601711 PubMed Central PMC6589689.
  8. Guilbaud, M, Gentil, C, Peccate, C, Gargaun, E, Holtzmann, I, Gruszczynski, C et al.. miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context. Skelet Muscle. 2018;8 (1):15. doi: 10.1186/s13395-018-0161-2. PubMed PMID:29703249 PubMed Central PMC5924477.
  9. Delalande, O, Molza, AE, Dos Santos Morais, R, Chéron, A, Pollet, É, Raguenes-Nicol, C et al.. Dystrophin's central domain forms a complex filament that becomes disorganized by in-frame deletions. J Biol Chem. 2018;293 (18):6637-6646. doi: 10.1074/jbc.M117.809798. PubMed PMID:29535188 PubMed Central PMC5936807.
  10. Julien, L, Chassagne, J, Peccate, C, Lorain, S, Piétri-Rouxel, F, Danos, O et al.. RFX1 and RFX3 Transcription Factors Interact with the D Sequence of Adeno-Associated Virus Inverted Terminal Repeat and Regulate AAV Transduction. Sci Rep. 2018;8 (1):210. doi: 10.1038/s41598-017-18604-3. PubMed PMID:29317724 PubMed Central PMC5760533.
  11. Godfrey, C, Desviat, LR, Smedsrød, B, Piétri-Rouxel, F, Denti, MA, Disterer, P et al.. Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med. 2017;9 (5):545-557. doi: 10.15252/emmm.201607199. PubMed PMID:28289078 PubMed Central PMC5412803.
  12. Pimentel, MR, Falcone, S, Cadot, B, Gomes, ER. In Vitro Differentiation of Mature Myofibers for Live Imaging. J Vis Exp. 2017; (119):. doi: 10.3791/55141. PubMed PMID:28117796 PubMed Central PMC5408763.
  13. Rendu, J, Montjean, R, Coutton, C, Suri, M, Chicanne, G, Petiot, A et al.. Functional Characterization and Rescue of a Deep Intronic Mutation in OCRL Gene Responsible for Lowe Syndrome. Hum Mutat. 2017;38 (2):152-159. doi: 10.1002/humu.23139. PubMed PMID:27790796 .
  14. Peccate, C, Mollard, A, Le Hir, M, Julien, L, McClorey, G, Jarmin, S et al.. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Hum Mol Genet. 2016;25 (16):3555-3563. doi: 10.1093/hmg/ddw201. PubMed PMID:27378686 .
  15. Gentil, C, Le Guiner, C, Falcone, S, Hogrel, JY, Peccate, C, Lorain, S et al.. Dystrophin Threshold Level Necessary for Normalization of Neuronal Nitric Oxide Synthase, Inducible Nitric Oxide Synthase, and Ryanodine Receptor-Calcium Release Channel Type 1 Nitrosylation in Golden Retriever Muscular Dystrophy Dystrophinopathy. Hum Gene Ther. 2016;27 (9):712-26. doi: 10.1089/hum.2016.041. PubMed PMID:27279388 .


WO2016198676A1 publication Critical patent/WO2016198676A1 COMBINED THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY Lorain et al.



Logo Malakoff Humanis

You cannot copy content of this page

Share This